COMMISSION DECISION

of 11.3.2016

on appointing members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals and patient organisations

(Text with EEA relevance)
COMMISSION DECISION

of 11.3.2016

on appointing members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals and patient organisations

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency¹, and in particular Article 61a(1) thereof,

Whereas:

(1) Article 61a(1)(c) and (d) of Regulation (EC) No 726/2004 provides that the Commission, after consulting the European Parliament, appoints representatives of healthcare professionals and patient organisations as members of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee.

(2) The Commission has undertaken a public call for expression of interest and consulted the European Parliament on the results of the evaluation of the applications received in the framework of this call, including the proposed reserve list.

(3) The members and alternates of the Committee should be appointed for a period of three years starting on 1 March 2016, which may be prolonged once.

(4) Where a member or alternate appointed by this decision is no longer capable of contributing efficiently to the work of the Committee or resigns, the Commission may replace this member or alternate from the reserve list, for the remaining duration of the mandate.

HAS DECIDED AS FOLLOWS:

Article 1

1. The following are hereby appointed as a member and alternate of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals for a term of three years:

   – Member: John Raymond ANDERSON,
   – Alternate: Kirsten MYHR.

2. The following are hereby appointed as a member and alternate of the Pharmacovigilance Risk Assessment Committee to represent patient organisations for a term of three years:

– Member: Marco GRECO,
– Alternate: Albert VAN DER ZEIJDEN.

Article 2

1. The following are hereby placed on a reserve list of members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals by order of merit:
   – Walter MARROCCO,
   – Bogumila Julia SOBKOWIAK.

2. The following are hereby placed on a reserve list of members and alternates of the Pharmacovigilance Risk Assessment Committee to represent patient organisations by order of merit:
   – Dimitros ATHANASIOU,
   – Giulio Maria CORBELLI,
   – Udo EHRMANN.

Article 3

This Decision shall take effect on the day of its adoption.

Done at Brussels, 11.3.2016

For the Commission
Vytenis ANDRIUKAITIS
Member of the Commission